Search

Your search keyword '"Bargou, Ralf C."' showing total 471 results
Start Over Author "Bargou, Ralf C."
471 results on '"Bargou, Ralf C."'

1. 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis

Author

Freitas, Florencio Porto, Alborzinia, Hamed, dos Santos, Ancély Ferreira, Nepachalovich, Palina, Pedrera, Lohans, Zilka, Omkar, Inague, Alex, Klein, Corinna, Aroua, Nesrine, Kaushal, Kamini, Kast, Bettina, Lorenz, Svenja M., Kunz, Viktoria, Nehring, Helene, Xavier da Silva, Thamara N., Chen, Zhiyi, Atici, Sena, Doll, Sebastian G., Schaefer, Emily L., Ekpo, Ifedapo, Schmitz, Werner, Horling, Aline, Imming, Peter, Miyamoto, Sayuri, Wehman, Ann M., Genaro-Mattos, Thiago C., Mirnics, Karoly, Kumar, Lokender, Klein-Seetharaman, Judith, Meierjohann, Svenja, Weigand, Isabel, Kroiss, Matthias, Bornkamm, Georg W., Gomes, Fernando, Netto, Luis Eduardo Soares, Sathian, Manjima B., Konrad, David B., Covey, Douglas F., Michalke, Bernhard, Bommert, Kurt, Bargou, Ralf C., Garcia-Saez, Ana, Pratt, Derek A., Fedorova, Maria, Trumpp, Andreas, Conrad, Marcus, and Friedmann Angeli, José Pedro

Published
2024
Full Text
View/download PDF

3. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Author

Gökbuget, Nicola, Kantarjian, Hagop M, Brüggemann, Monika, Stein, Anthony S, Bargou, Ralf C, Dombret, Hervé, Fielding, Adele K, Heffner, Leonard, Rigal-Huguet, Françoise, Litzow, Mark, O’Brien, Susan, Zugmaier, Gerhard, Gao, Shan, Nagorsen, Dirk, Forman, Stephen J, and Topp, Max S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Pediatric Research Initiative, Childhood Leukemia, Cancer, Pediatric Cancer, Clinical Research, Rare Diseases, Genetics, Pediatric, Hematology, Detection, screening and diagnosis, Aetiology, 4.2 Evaluation of markers and technologies, 2.1 Biological and endogenous factors, Adolescent, Adult, Aged, Antibodies, Bispecific, Antineoplastic Agents, Clinical Trials, Phase II as Topic, Combined Modality Therapy, Drug Resistance, Neoplasm, Female, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Recurrence, Treatment Outcome, Young Adult, Cardiovascular medicine and haematology
Abstract

Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring and decision making. Limited data are available on the prognostic value of MRD response after relapse. We evaluated the relationship between MRD response and outcomes in blinatumomab-treated adults with relapsed/refractory (R/R) B-cell precursor ALL. Of 90 patients with complete remission (CR) or CR with partial hematologic recovery (CRh), 64 (71.1%) achieved a complete MRD response (no detectable individual rearrangements of immunoglobulin/T-cell receptor genes by polymerase chain reaction [PCR] at a minimum sensitivity level of 10-4). Eleven patients had MRD

Published
2019

7. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

Author

Penny, Hweixian Leong, primary, Hainline, Kelly, additional, Theoharis, Nathaniel, additional, Wu, Bin, additional, Brandl, Christian, additional, Webhofer, Christian, additional, McComb, Mason, additional, Wittemer-Rump, Sabine, additional, Koca, Gökben, additional, Stienen, Sabine, additional, Bargou, Ralf C., additional, Hummel, Horst-Dieter, additional, Loidl, Wolfgang, additional, Grüllich, Carsten, additional, Eggert, Tobias, additional, Tran, Ben, additional, and Mytych, Daniel T., additional

Published
2023
Full Text
View/download PDF

9. Spectrum and functional validation of PSMB5 mutations in multiple myeloma

Author

Barrio, Santiago, Stühmer, Thorsten, Da-Viá, Matteo, Barrio-Garcia, Clara, Lehners, Nicola, Besse, Andrej, Cuenca, Isabel, Garitano-Trojaola, Andoni, Fink, Severin, Leich, Ellen, Chatterjee, Manik, Driessen, Christoph, Martinez-Lopez, Joaquin, Rosenwald, Andreas, Beckmann, Roland, Bargou, Ralf C., Braggio, Esteban, Stewart, A. Keith, Raab, Marc S., Einsele, Hermann, and Kortüm, K. Martin

Published
2019
Full Text
View/download PDF

10. Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate

Author

Brünnert, Daniela, primary, Seupel, Raina, additional, Goyal, Pankaj, additional, Bach, Matthias, additional, Schraud, Heike, additional, Kirner, Stefanie, additional, Köster, Eva, additional, Feineis, Doris, additional, Bargou, Ralf C., additional, Schlosser, Andreas, additional, Bringmann, Gerhard, additional, and Chatterjee, Manik, additional

Published
2023
Full Text
View/download PDF

17. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Author

Topp, Max S, Gökbuget, Nicola, Stein, Anthony S, Zugmaier, Gerhard, O'Brien, Susan, Bargou, Ralf C, Dombret, Hervé, Fielding, Adele K, Heffner, Leonard, Larson, Richard A, Neumann, Svenja, Foà, Robin, Litzow, Mark, Ribera, Josep-Maria, Rambaldi, Alessandro, Schiller, Gary, Brüggemann, Monika, Horst, Heinz A, Holland, Chris, Jia, Catherine, Maniar, Tapan, Huber, Birgit, Nagorsen, Dirk, Forman, Stephen J, and Kantarjian, Hagop M

Published
2015
Full Text
View/download PDF

19. Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Author

Shah, Pooja, primary, Stuehmer, Thorsten, additional, Haertle, Larissa, additional, Bruennert, Daniela, additional, Munawar, Umair, additional, Leich, Ellen, additional, Kraus, Sabrina, additional, Hudecek, Michael, additional, Chatterjee, Manik, additional, Schlosser, Andreas, additional, Kortuem, Martin, additional, Bargou, Ralf C, additional, Einsele, Hermann, additional, Berberich-Siebelt, Friederike, additional, and Steinbrunn, Torsten, additional

Published
2022
Full Text
View/download PDF

20. P-075: CD200 expression in multiple myeloma is regulated by P53 and exerts its function as immune checkpoint on T cells via DOK2

Author

Shah, Pooja, primary, Stühmer, Thorsten, additional, Haertle, Larissa, additional, Brünnert, Daniela, additional, Munawar, Umair, additional, Leich, Ellen, additional, Solimando, Antonio G., additional, Kraus, Sabrina, additional, Hudecek, Michael, additional, Chatterjee, Manik, additional, Schlosser, Andreas, additional, Kortüm, K. Martin, additional, Rosenwald, Andreas, additional, Bargou, Ralf C., additional, Einsele, Hermann, additional, Berberich-Siebelt, Friederike, additional, and Steinbrunn, Torsten, additional

Published
2022
Full Text
View/download PDF

23. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Author

Klinger, Matthias, Brandl, Christian, Zugmaier, Gerhard, Hijazi, Youssef, Bargou, Ralf C., Topp, Max S., Gökbuget, Nicola, Neumann, Svenja, Goebeler, Mariele, Viardot, Andreas, Stelljes, Matthias, Brüggemann, Monika, Hoelzer, Dieter, Degenhard, Evelyn, Nagorsen, Dirk, Baeuerle, Patrick A., Wolf, Andreas, and Kufer, Peter

Published
2012
Full Text
View/download PDF

25. CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Author

Shah, Pooja, primary, Stuehmer, Thorsten, additional, Bruennert, Daniela, additional, Munawar, Umair, additional, Leich, Ellen, additional, Kraus, Sabrina, additional, Hudecek, Michael, additional, Chatterjee, Manik, additional, Schlosser, Andreas, additional, Bargou, Ralf C, additional, Einsele, Hermann, additional, Berberich-Siebelt, Friederike, additional, and Steinbrunn, Torsten, additional

Published
2021
Full Text
View/download PDF

26. OAB-017: Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells

Author

Shah, Pooja, primary, Stühmer, Thorsten, additional, Brünnert, Daniela, additional, Munawar, Umair, additional, Leich, Ellen, additional, Kraus, Sabrina, additional, Chatterjee, Manik, additional, Schlosser, Andreas, additional, Bargou, Ralf C., additional, Einsele, Hermann, additional, Berberich-Siebelt, Friederike, additional, and Steinbrunn, Torsten, additional

Published
2021
Full Text
View/download PDF

31. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Author

Wermke, Martin, primary, Kraus, Sabrina, additional, Ehninger, Armin, additional, Bargou, Ralf C., additional, Goebeler, Maria-Elisabeth, additional, Middeke, Jan Moritz, additional, Kreissig, Carla, additional, von Bonin, Malte, additional, Koedam, Jan, additional, Pehl, Michael, additional, Bornhäuser, Martin, additional, Einsele, Hermann, additional, Ehninger, Gerhard, additional, and Cartellieri, Marc, additional

Published
2021
Full Text
View/download PDF

35. A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).

Author

Melero, Ignacio, primary, Calvo, Emiliano, additional, Dummer, Reinhard, additional, Garralda, Elena, additional, Schuler, Martin H., additional, Goebeler, Maria-Elisabeth, additional, Bargou, Ralf C., additional, Gromke, Tanja, additional, Tabernero, Josep, additional, Ramelyte, Egle, additional, De Miguel, Maria, additional, Sanmamed, Miguel F., additional, Rodriguez-Ruiz, Maria E., additional, Fettes, Petra, additional, Klar, Kathrin, additional, Ruediger, Manfred, additional, Schuberth-Wagner, Christine, additional, Haake, Markus, additional, Wischhusen, Joerg, additional, and Leo, Eugen, additional

Published
2021
Full Text
View/download PDF

36. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Bargou, Ralf C., Schweizerische Gesellschaft Für Hämatologie, Borchmann, Peter, Hudecek, Michael, Viardot, Andreas, Bergwelt, Michael Von, Greinix, Hildegard, Schweizerische Gesellschaft Für Medizinische Onkologie, Rössig, Claudia, Bader, Peter, Baumgarten, Louisa Von, Subklewe, Marion, Bücklein, Veit Leonhard, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Topp, Max S., Mielke, Stephan, Bethge, Wolfgang Andreas, Mackensen, Andreas, Müller, Antonia Maria Susanne, Schmitt, Michael, Blumenberg, Viktoria, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Jäger, Ulrich, and Einsele, Hermann

Subjects
Medizin und Gesundheit
Published
2020
Full Text
View/download PDF

37. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Author

Gökbuget, Nicola, Zugmaier, Gerhard, Dombret, Hervé, Stein, Anthony, Bonifacio, Massimiliano, Graux, Carlos, Faul, Christoph, Brüggemann, Monika, Taylor, Kate, Mergen, Noemi, Reichle, Albrecht, Horst, Heinz August, Havelange, Violaine, Topp, Max S., Bargou, Ralf C., Gökbuget, Nicola, Zugmaier, Gerhard, Dombret, Hervé, Stein, Anthony, Bonifacio, Massimiliano, Graux, Carlos, Faul, Christoph, Brüggemann, Monika, Taylor, Kate, Mergen, Noemi, Reichle, Albrecht, Horst, Heinz August, Havelange, Violaine, Topp, Max S., and Bargou, Ralf C.

Abstract

Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE® immuno-oncotherapy, 15 µg/m2/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59·8 months, median survival (months) was 36·5 (95% CI: 22.0–not reached [NR]). Median survival was NR (29.5–NR) for complete MRD responders (n = 84) and 14.4 (3.8–32.3) for MRD non-responders (n = 23; p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7–NR) (n = 61) and 16.5 (1.1–NR) (n = 10; p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible.

Published
2020

41. Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

Author

Munawar, Umair, Rasche, Leo, Müller, Nicole, Vogt, Cornelia, Da-Via, Matteo, Haertle, Larissa, Arampatzi, Panagiota, Dietrich, Sascha, Roth, Markus, Garitano-Trojaola, Andoni, Steinhardt, Maximilian Johannes, Strifler, Susanne, Gallardo, Miguel, Martinez-Lopez, Joaquin, Bargou, Ralf C., Heckel, Tobias, Einsele, Hermann, Stühmer, Thorsten, Kortüm, K. Martin, and Barrio, Santiago

Published
2019
Full Text
View/download PDF

42. Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Author

Hummel, Horst-Dieter, primary, Kufer, Peter, additional, Grüllich, Carsten, additional, Seggewiss-Bernhardt, Ruth, additional, Deschler-Baier, Barbara, additional, Chatterjee, Manik, additional, Goebeler, Maria-Elisabeth, additional, Miller, Kurt, additional, de Santis, Maria, additional, Loidl, Wolfgang, additional, Dittrich, Christian, additional, Buck, Andreas, additional, Lapa, Constantin, additional, Thurner, Annette, additional, Wittemer-Rump, Sabine, additional, Koca, Gökben, additional, Boix, Oliver, additional, Döcke, Wolf-Dietrich, additional, Finnern, Ricarda, additional, Kusi, Helena, additional, Ajavon-Hartmann, Antoinette, additional, Stienen, Sabine, additional, Sayehli, Cyrus Michael, additional, Polat, Bülent, additional, and Bargou, Ralf C, additional

Published
2020
Full Text
View/download PDF

43. Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Author

Goekbuget, Nicola, primary, Wermann, Wiba Keke, additional, Schwartz, Stefan, additional, Hüttmann, Andreas, additional, Faul, Christoph, additional, Raffel, Simon, additional, Viardot, Andreas, additional, Fiedler, Walter, additional, Alakel, Nael, additional, Stelljes, Matthias, additional, Subklewe, Marion, additional, Wäsch, Ralph, additional, Martin, Sonja, additional, Jung, Wolfram, additional, Vucinic, Vladan, additional, Kondakci, Mustafa, additional, Fransecky, Lars R., additional, Heidenreich, Daniela, additional, Wendelin, Knut, additional, Hermann, Julian, additional, Serve, Hubert, additional, Bargou, Ralf C, additional, Topp, Max S., additional, and Brüggemann, Monika, additional

Published
2020
Full Text
View/download PDF

46. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Author

Gökbuget, Nicola, primary, Zugmaier, Gerhard, additional, Dombret, Hervé, additional, Stein, Anthony, additional, Bonifacio, Massimiliano, additional, Graux, Carlos, additional, Faul, Christoph, additional, Brüggemann, Monika, additional, Taylor, Kate, additional, Mergen, Noemi, additional, Reichle, Albrecht, additional, Horst, Heinz-August, additional, Havelange, Violaine, additional, Topp, Max S., additional, and Bargou, Ralf C., additional

Published
2020
Full Text
View/download PDF

47. Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).

Author

Hummel, Horst-Dieter, primary, Kufer, Peter, additional, Grüllich, Carsten, additional, Deschler-Baier, Barbara, additional, Chatterjee, Manik, additional, Goebeler, Maria-Elisabeth, additional, Miller, Kurt, additional, De Santis, Maria, additional, Loidl, Wolfgang C., additional, Buck, Andreas, additional, Wittemer-Rump, Sabine, additional, Koca, Goekben, additional, Boix, Oliver, additional, Doecke, Wolf-Dietrich, additional, Stienen, Sabine, additional, Sayehli, Cyrus, additional, and Bargou, Ralf C., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results